Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United States
Authors: EW Hofstatter, D Lannin, N Horowitz, B Killelea, T Tsangaris, L Pusztai, G Chung, T Sanft, M DiGiovanna, M AbuKhalaf, S Mougalian, A Chagpar
Journal: Cancer Research (2013)

Abstract Introduction: Tamoxifen and raloxifene have been shown to reduce the risk of breast cancer by up to 50%, yet the uptake of these agents remains poor. We sought to determine factors associated with chemoprevention uptake in a nationally representative sample. Methods: The National Health Interview Survey (NHIS) is a population-based survey conducted annually by the CDC and is designed to be representative of the non-institutionalized civilian population in the United States. We utilized data from the 2010 NHIS cancer supplement to determine factors associated with chemoprevention uptake in women ≥ 35 years of age. Statistical analyses were conducted using SUDAAN software. Results: In 2010, 10,959 women ≥ 35 years of age were surveyed, representing 83,377,082 people in the population. Of these, 0.21% reported taking chemoprevention, using either tamoxifen or raloxifene. On bivariate analyses, factors correlating with chemoprevention uptake included age, race/ethnicity, education, insurance, income and geographic region (see Table). Interestingly, MRI use, family history of premenopausal breast cancer in first degree relatives, and personal risk perception were not associated with chemoprevention use. On multivariate analysis, education and income remained independent predictors of chemoprevention use. Conclusion: Approximately 0.2% of women take chemoprevention. It is concerning that sociodemographic factors of education and income are independent predictors of the use of chemopreventive agents for breast cancer, while risk perception and family history do not seem to correlate with uptake rates. These findings are a call to action for improved education and counseling of those who are at greatest risk, and highlight potential disparities in access to appropriate chemoprevention across all sociodemographic groups. Bivariate and Multivariate Analyses of Factors Correlated with Chemoprevention UptakeFactorBivariate AnalysisMultivariate Analysis Chemoprevention (%)No Chemoprevention (%)p-valueOR (95% CI)p-valueAge 0.0481 0.1087&amp;lt; 40 yr3.2211.93 1.00 40-49 yr5.8726.11 0.78 (0.05-12.44) 50-59 yr11.7024.88 1.44 (0.10-21.43) 60-69 yr23.8218.54 3.15 (0.32-31.41) 70-79 yr44.4110.77 8.62 (0.78-94.75) 80+ yr10.997.77 1.53 (0.10-23.66) Race/ethnicity 0.0006 0.8372Hispanic3.9011.06 00.81 (0.11-5.85) White96.1071.63 1.00 Black011.80 - Asian04.61 - Other00.89 - Education 0.0371 &amp;lt;0.0001&amp;lt; Grade 127.1214.15 1.00 High School25.8627.73 1.86 (0.35-9.75) Some college/Assoc21.4229.97 1.85 (0.36-9.45) Bachelors15.5917.49 1.44 (0.13-16.35) Masters11.708.37 3.23 (0.41-25.14) Prof/Doctorate18.302.28 25.22 (4.30-147.87) Insurance 0.0002 0.0686Not covered012.44 - Medicare72.6129.38 1.00 Medicaid3.224.50 2.38 (0.22-26.15) Military01.74 - Private24.1751.94 0.28 (0.06-1.26) Income 0.0005 0.0306&amp;lt;$35K32.3934.53 1.00 $35K-$74,99926.1131.53 0.97 (0.21-4.42) $75K-$99,999012.08 - $100K+41.6021.86 3.78 (0.94-15.22) Region 0.0441 0.1649Northeast27.9318.62 1.00 Midwest31.6022.88 0.92 (0.32-2.64) South34.4935.66 0.65 (0.21-2.04) West5.9822.84 0.16 (0.03-0.86) Oophorectomy40.1115.160.08132.17 (0.77-6.09)0.1404MRI use2.315.170.2597 Family History2.315.130.2601 Risk Perception 0.1451 High41.5212.50 Average25.8947.49 Low32.5940.01 Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-13-05.